Targeted Cancer Therapy Market By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, CAR-T Cell Therapy, Tyrosine Kinase Inhibitors, Angiogenesis Inhibitors), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukaemia, Lymphoma, Others), By Dosage Form (Oral, Injectable, Topical, and Others), By End-User (Hospitals, Cancer Research Centers, Specialty Clinics), Global Market Size, Segmental analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Targeted Cancer Therapy Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. A shift toward personalized medicine enhances the appeal of targeted therapies.

3.2.2. Increased understanding of cancer genomics leads to the development of more precise therapies.

3.2.3. Growing telehealth services facilitate access to specialized care and consultations for targeted therapies.

3.3. Key industry pitfalls & challenges

3.3.1. The high cost of targeted therapies can limit access for patients and healthcare systems.

3.3.2. Complexity in treatment regimens may deter some healthcare providers.

3.3.3. The approval process can be lengthy and complicated, hindering market entry.

3.4. Market Opportunities

3.4.1. Utilizing digital health technologies to enhance patient management and therapy adherence.

3.4.2. Creating tests that identify patients eligible for targeted therapies can enhance treatment success rates.

3.4.3. Expanding into emerging markets with rising healthcare needs offers significant growth potential.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Targeted Cancer Therapy Market, Therapy Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Monoclonal Antibodies

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Immune Checkpoint Inhibitors

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. CAR-T Cell Therapy

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Tyrosine Kinase Inhibitors

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Angiogenesis Inhibitors

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Targeted Cancer Therapy Market, Cancer Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.1.3. Market Size and Forecast, 2025-2035 (USD Billion)

5.2. Breast Cancer

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Lung Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Colorectal Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Prostate Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Leukemia

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Lymphoma

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Targeted Cancer Therapy Market, Dosage Form Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Dosage Form, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oral

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Injectable

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Topical

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Others

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Targeted Cancer Therapy Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Cancer Research Centers

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Specialty Clinics

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Others

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Targeted Cancer Therapy Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Therapy Type, 2025-2035

8.2.3. North America Market Revenue, By Cancer Type, 2025-2035

8.2.4. North America Market Revenue, By Dosage Form, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Therapy Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Cancer Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Dosage Form, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Therapy Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Cancer Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Dosage Form, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Therapy Type, 2025-2035

8.3.3. Europe Market Revenue, By Cancer Type, 2025-2035

8.3.4. Europe Market Revenue, By Dosage Form, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Therapy Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Cancer Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Dosage Form, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Therapy Type, 2025-2035

8.3.7.2. France Market Revenue, By Cancer Type, 2025-2035

8.3.7.3. France Market Revenue, By Dosage Form, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Therapy Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Cancer Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Dosage Form, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Therapy Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Cancer Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Dosage Form, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Therapy Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Cancer Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Dosage Form, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Dosage Form, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Dosage Form, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Therapy Type, 2025-2035

8.4.6.2. China Market Revenue, By Cancer Type, 2025-2035

8.4.6.3. China Market Revenue, By Dosage Form, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Therapy Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Cancer Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Dosage Form, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Therapy Type, 2025-2035

8.4.8.2. India Market Revenue, By Cancer Type, 2025-2035

8.4.8.3. India Market Revenue, By Dosage Form, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Therapy Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Cancer Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Dosage Form, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Therapy Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Cancer Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Dosage Form, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Therapy Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Cancer Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Dosage Form, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Dosage Form, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Therapy Type, 2025-2035

8.5.3. Latin America Market Revenue, By Cancer Type, 2025-2035

8.5.4. Latin America Market Revenue, By Dosage Form, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Therapy Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Cancer Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Dosage Form, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Therapy Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Cancer Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Dosage Form, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Therapy Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Cancer Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Dosage Form, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Cancer Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Dosage Form, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Therapy Type, 2025-2035

8.6.3. MEA Market Revenue, By Cancer Type, 2025-2035

8.6.4. MEA Market Revenue, By Dosage Form, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Therapy Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Cancer Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Dosage Form, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Therapy Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Cancer Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Dosage Form, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Dosage Form, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. Roche

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Novartis

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Pfizer

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Merck & Co.

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Bristol-Myers Squibb

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. AstraZeneca

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Amgen

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Celgene

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Eli Lilly

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Sanofi

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Johnson & Johnson

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Regeneron Pharmaceuticals

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Takeda Pharmaceutical Company

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Blueprint Medicines

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis